Evaluation of tumor immune microenvironment for PD-L1 score and tumor infiltrating lymphocytes in high grade osteosarcomas and their correlation with disease progression. This is an ASCO Meeting ...
Ligand Pharmaceuticals LGND announced that it has signed an agreement to merge its subsidiary Pelican Technology Holdings, Inc., with Primordial Genetics to create a new stand-alone private company ...
At its R&D event held on Dec 12, Ligand Pharmaceuticals LGND provided an overview of its business model and issued fresh guidance outlook for the next five years. Ligand issued fresh guidance for 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results